Association of Pisa Syndrome With Mortality in Patients With Parkinson's Disease

In Parkinson's disease, Pisa syndrom (PS) has been associated with disease stage and severity, combined treatment with levodopa and dopamine agonists, gait disorders, and comorbidities. Some forms of PS are potentially reversible; nevertheless, little is known about the impact of this syndrome on survival.
Source: Journal of the American Medical Directors Association - Category: Health Management Authors: Tags: Original Study - Brief Report Source Type: research

Related Links:

Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Some wearable solutions exploiting on-body acceleration sensors have been proposed to recognize Freezing of Gait (FoG) in people affected by Parkinson Disease (PD). Once a FoG event is detected, these systems generate a sequence of rhythmic stimuli to allo...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
This study examined the effects of a Strength, Hope, and Resources Program for People with PD (SHARP-PWP), based on the principles of positive psychology.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Source Type: research
Source: Clinical Nutrition - Category: Nutrition Authors: Tags: Letter to the Editor Source Type: research
AbstractPurposePsychotic symptoms in Parkinson ’s disease are relatively common and include hallucinations, illusions, and delusions. Psychosis is a major cause of disability and is one of the most distressing symptoms for both patients and caregivers. The management of psychosis is often complex and challenging and involves determining the de gree and severity of psychotic symptoms and whether intervention is required. In this review, the authors describe the phenomenology and risk factors of Parkinson’s disease psychosis (PDP) and current evidence-based treatment options.Recent findingsIn randomized, double-b...
Source: Current Treatment Options in Psychiatry - Category: Psychiatry Source Type: research
Conclusions: To the best of our knowledge, this is the first study investigating verbal memory consolidation in PD. Results suggested that impairment is possibly related to the late phase of consolidation of verbal memory in neocortex.
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Publication date: December 2019Source: Journal of Clinical Neuroscience, Volume 70Author(s): Hülya Olgun Yazar, Tamer Yazar, Murat CihanAbstractAimIn our study, we aimed to collect data for the hypothesis that Galectin-3 might be used as a new prognostic and therapeutic biomarker in Idiopathic Parkinson's Disease (IPD).MethodIn this prospective and cross-sectional study, the Unified Parkinson's Disease Rating Scale (UPDRS) and Modified Hoehn and Yahr (H&Y) scales were applied to each patient diagnosed as IPD according to the UK Brain Bank diagnostic criteria. The control group consisted of healthy individuals with the...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Condition:   Parkinson's Disease Intervention:   Behavioral: Wellness Recovery Program Sponsor:   Wake Forest University Health Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson Disease Intervention:   Other: hyperthermic baths Sponsor:   Nanjing First Hospital, Nanjing Medical University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson's Disease Interventions:   Drug: Pimavanserin;   Other: Placebo;   Drug: Quetiapine Sponsor:   ACADIA Pharmaceuticals Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Carbidopa/Levodopa | Health Management | Monaco Health | Parkinson's Disease | Study